Reanalysis of rosiglitazone meta-analysis raises questions
Links shared publicly online about this topic.
A new analysis of the same 42 trials, but using a number of different statistical methods to account for all the zero events, found no significant increase in either MI or CV death and highlights flaws in the original study. In response, Nissen counters that the report is now neither useful nor relevant in the wake of the FDA hearing. The FDA panel chair says the whole saga highlights the need for drug-approval reform. (Diamond G et al. Ann Intern Med; published online before print August 6, 200 View full resource at theheart.org
Tags: Diabetes Type 2 Medication, Diabetes Medication, FDA, Avandia, Avandamet, Avandaryl
Most Recently Shared on July 13, 2010 at 10:19 pm By: